Allogeneic transplant for PTCL – pro
T-cell lymphomas are a relatively uncommon form of non-Hodgkin’s lymphoma (NHL) that generally do not respond as well to treatment as B-cell NHL. Peripheral T-cell lymphoma accounts for about one in 100 of all cases of NHL. It can occur at any age from young adulthood to old age and is slightly more common in men. There are various subtypes, some related to HIV or HTLV. Management of these disorders has been modeled after the treatment of aggressive B-cell lymphomas. For peripheral T-cell lymphoma, on p. TCELL-4 of 2022 NCCN Peripheral T-Cell lymphoma guideline, an allogeneic or autologous stem cell transplant is recommended for patients with partial or complete response.
NCCN PTCL 2022
Mamez AC, DuPont A, Blaise D, Chevallier P, Forcade E, Ceballos P, Mohty M, Suarez F, Beguin Y, Peffault De Latour R, Rubio MT, Tournilhac O, Nguyen S. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). J Hematol Oncol. 2020 May 19; 13(1): 56.
Du J, Yu D, Han X, Zhu L, Huang Z. Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021 May 3; 4(5): e219807.